Colorectal Cancer Clinical Trial
Official title:
An Open-Label, Phase 1b/2 Study to Evaluate the Safety and Efficacy of Fruquintinib in Combination With Tislelizumab in Patients With Advanced Solid Tumors
Verified date | February 2024 |
Source | Hutchmed |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is an open-label, multi-center, non-randomized, Phase 1b/2 study to assess the safety and efficacy of fruquintinib in combination with tislelizumab in patients with locally advanced or metastatic solid tumors. This study will be conducted in 2 parts; a Safety Lead-in Phase (Part 1) and a Dose Expansion Phase (Part 2). The Safety Lead-in Phase, open to any-comer solid tumors, will determine the RP2D. The RP2D will be administered to 3 cohorts of patients in the Dose Expansion Phase. - Cohort A: Advanced or Metastatic Triple Negative Breast Cancer (TNBC) (IO-treated) - Cohort B: Advanced or Metastatic Triple Negative Breast Cancer (TNBC) (IO-Naïve) - Cohort C: Advanced or Metastatic Endometrial Cancer (EC) (IO-Naïve) - Cohort D: Advanced or Metastatic Colorectal Cancer (mCRC) (IO-Naïve)
Status | Active, not recruiting |
Enrollment | 112 |
Est. completion date | November 2024 |
Est. primary completion date | July 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Willing and able to provide informed consent signed by study patient or legally acceptable representative, as specified by health authorities and institutional guidelines; 2. Age =18 years; 3. Histologically or cytologically documented, advanced or metastatic Triple Negative Breast Cancer, histologically or cytologically documented, advanced or metastatic endometrial carcinoma, histologically or cytologically confirmed advanced or metastatic, unresectable adenocarcinoma of the colon or rectum. 4. Tumor tissue (archival or fresh tumor tissues as formalin-fixed paraffin-embedded blocks or approximately 15 unstained slides) for central laboratory assessment. 5. Eastern Cooperative Oncology Group (ECOG) Performance Status =1. 6. At least 1 measurable lesion as defined by RECIST v1.1. Exclusion Criteria: 1. Has at screening any central nervous system metastasis and/or leptomeningeal disease. 2. Except for Cohort A, Prior therapy targeting CTLA-4, PD-1, PD-L1 or programmed cell death protein ligand-2 (PD-L2) or any other antibody or drug specifically targeting T-cell costimulation or checkpoint pathways. 3. Prior treatment with a VEGFR-TKI or anti-VEGFR antibody (eg, ramucirumab). 4. Except for Cohort D, prior treatment with an anti-VEGFR antibody (eg, bevacizumab). 5. Tumor tissue (archival or fresh tumor tissues as formalin-fixed paraffin-embedded blocks or approximately 15 unstained slides) for central laboratory assessment. 6. Active autoimmune diseases or history of autoimmune diseases that may relapse, or history of interstitial lung disease, noninfectious pneumonitis, or uncontrolled lung diseases including but not limited to pulmonary fibrosis, acute lung diseases, etc. NOTE: Other protocol defined Inclusion/Exclusion criteria may apply |
Country | Name | City | State |
---|---|---|---|
United States | Messino Cancer Center | Asheville | North Carolina |
United States | University of Colorado | Aurora | Colorado |
United States | HOC AON Baton Rouge / Sarah Cannon | Baton Rouge | Louisiana |
United States | Beverly Hills Cancer Center | Beverly Hills | California |
United States | Tennessee Oncology-Chattanooga | Chattanooga | Tennessee |
United States | The University of Texas MD Anderson Cancer Center | Houston | Texas |
United States | Tennesse Oncology | Nashville | Tennessee |
United States | Vanderbilt Ingram Cancer Center | Nashville | Tennessee |
United States | Oklahoma University Stephenson Cancer Center | Oklahoma City | Oklahoma |
United States | Mayo Clinic Arizona | Phoenix | Arizona |
United States | Florida Cancer Specialists - FCS South | Port Charlotte | Florida |
United States | Women and Infants Hospital of Rhode Island | Providence | Rhode Island |
United States | Florida Cancer Center North | Saint Petersburg | Florida |
United States | Highlands Oncology | Springdale | Arkansas |
United States | Florida Cancer Specialists Panhandle | Tallahassee | Florida |
United States | Florida Cancer Specialists - East (FCS East) | West Palm Beach | Florida |
Lead Sponsor | Collaborator |
---|---|
Hutchison Medipharma Limited | BeiGene |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Adverse Events by type, frequency, and severity | To assess the safety and tolerability by monitoring AEs characterized by type, frequency, severity per NCI-CTCAE v5.0 | At the end of Cycle 1 (each cycle is 28 days) | |
Primary | Recommended Phase 2 Dose | To confirm the RP2D of fruquintinib in combination with tislelizumab | At the end of Cycle 1 (each cycle is 28 days) | |
Primary | Objective Response Rate | To evaluate the objective response rate (ORR) as assessed by the investigator in subjects with advanced or metastatic TNBC or EC or CRC when treated with fruquintinib in combination with tislelizumab | Up to 18 months | |
Secondary | Maximum plasma concentrations of fruquintinib with blood sampling | Blood samples will be taken to measure levels of fruquintinib | Up to 18 months | |
Secondary | Maximum serum concentrations of tislelizumab with blood sampling | Blood samples will be taken to measure levels of tislelizumab | Up to 18 months | |
Secondary | Progression-free Survival | To further evaluate efficacy of fruquintinib in combination with tislelizumab in patients with advanced or metastatic TNBC or EC per investigator assessment | Up to 24 months | |
Secondary | Changes from baseline in biomarkers | To detect the expression biomarkers in tumor tissues of patients | Up to 18 months | |
Secondary | Incidence of ADA to tislelizumab | To evaluate the immunogenicity of fruquintinib in combination with tislelizumab | Up to 18 months | |
Secondary | Disease Control Rate (DCR) | The incidence of complete response, partial response, and stable disease | Up to 24 months | |
Secondary | Clinical Benefit Rate | The incidence of partial response and stable disease | Up to 24 months | |
Secondary | Duration of Response | he duration between the date the criteria for complete response or partial response was first measured (first record shall prevail) and the date of disease recurrence or progression as objectively recroded | Up to 24 months | |
Secondary | Overall Survival | The period from date of enrollment to date of death | Up to 36 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05400122 -
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
|
Phase 1 | |
Active, not recruiting |
NCT05551052 -
CRC Detection Reliable Assessment With Blood
|
||
Completed |
NCT00098787 -
Bevacizumab and Oxaliplatin Combined With Irinotecan or Leucovorin and Fluorouracil in Treating Patients With Metastatic or Recurrent Colorectal Cancer
|
Phase 2 | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT05425940 -
Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer
|
Phase 3 | |
Suspended |
NCT04595604 -
Long Term Effect of Trimodal Prehabilitation Compared to ERAS in Colorectal Cancer Surgery.
|
N/A | |
Completed |
NCT03414125 -
Effect of Mailed Invites of Choice of Colonoscopy or FIT vs. Mailed FIT Alone on Colorectal Cancer Screening
|
N/A | |
Completed |
NCT02963831 -
A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies
|
Phase 1/Phase 2 | |
Recruiting |
NCT05489211 -
Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
|
Phase 2 | |
Terminated |
NCT01847599 -
Educational Intervention to Adherence of Patients Treated by Capecitabine +/- Lapatinib
|
N/A | |
Completed |
NCT05799976 -
Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure
|
N/A | |
Recruiting |
NCT03874026 -
Study of Folfiri/Cetuximab in FcGammaRIIIa V/V Stage IV Colorectal Cancer Patients
|
Phase 2 | |
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT03167125 -
Participatory Research to Advance Colon Cancer Prevention
|
N/A | |
Completed |
NCT03181334 -
The C-SPAN Coalition: Colorectal Cancer Screening and Patient Navigation
|
N/A | |
Recruiting |
NCT04258137 -
Circulating DNA to Improve Outcome of Oncology PatiEnt. A Randomized Study
|
N/A | |
Recruiting |
NCT05568420 -
A Study of the Possible Effects of Medication on Young Onset Colorectal Cancer (YOCRC)
|
||
Recruiting |
NCT02972541 -
Neoadjuvant Chemotherapy Verse Surgery Alone After Stent Placement for Obstructive Colonic Cancer
|
N/A | |
Completed |
NCT02876224 -
Study of Cobimetinib in Combination With Atezolizumab and Bevacizumab in Participants With Gastrointestinal and Other Tumors
|
Phase 1 | |
Completed |
NCT01943500 -
Collection of Blood Specimens for Circulating Tumor Cell Analysis
|
N/A |